Zoetis Launches Simparica In UK
Zoetis has launched SimparicaTM, a once-monthly oral medication for the treatment of flea, tick and mite infestations in dogs beginning at eight weeks of age. Simparica acts quickly and provides continuous protection for 35 days without losing efficacy at the end of the month.
Delivered as a tasty chewable tablet, Simparica kills a broad spectrum of ectoparasites: Ctenocephalides canis, Ctenocephalides felis, Ixodes ricinus, Ixodes hexagonus, Dermacentor reticulatus, Rhipicephalus sanguineus, and Sarcoptes scabiei. The medication can also be used as part of a treatment strategy for Flea Allergy Dermatitis (FAD) and laboratory evidence shows efficacy for Demodex Canis and Otodectes Cynotis.
Zoetis believes that Simparica’s ability to provide continuous protection up to and beyond the monthly treatment period is very important for pet owners. Sixty three per cent of owners confess to giving flea and tick treatment later than when it was due, with the median being 5 days late.¹ Simparica gives vets and forgetful pet owners the peace of mind of extended duration of activity helping to minimise the potential risk of protection gaps.
Simparica is effective against both Ctenocephalides felis and Ctenocephalides canis flea infestations in dogs.² It starts to kill fleas quickly within three hours³ and continues to kill fleas with immediate effect for at least 35 days². The product also protects dogs against infestations with the most common ticks found to infest dogs in Europe2,4, including Dermacentor reticulatus, the species associated with the disease babesiosis, which has recently been reported in the UK. It’s also the only treatment for Ixodes hexagonus one of the most prevalent ticks in the UK. The killing effect against Ixodes ricinus starts within 8 hours after a single oral administration and over 96% are killed within 24 hours.4
“With Simparica, we bring to the market an advanced parasiticide solution, helping to deliver improved client and pet owner satisfaction,” says Ned Flaxman, companion animal business unit director at Zoetis. “The chewable tablets are easy to administer and readily accepted by dogs. But more importantly, Simparica helps vets and dog owners minimise the potential risk of protection gaps, as it acts very fast to kill fleas and ticks and performs for at least 35 days without losing efficacy — well beyond the monthly treatment period.
“With its rapid onset, robust duration of activity and very good safety profile, Simparica is the only oral isoxazoline indicated for four species of ticks in Europe including Ixodes hexagonus and the two species of fleas, dogs are most frequently infested with. Unlike most treatments, Simparica protects from both types of ectoparasites for the same duration.”
For more information please speak to your account manager or contact customer support on 0854 300 8034.
1 UK pet owner testing, November 4, 2015, prepared by the link group.
2 Simparica SPC
3 Zoetis study A166C-US-12-113
4 Six R, Geurden T, et al. Zoetis Study Number A166C-IE-13-191.
More from Zoetis
- Zoetis Launches the First Oral Vaccine for Dogs in Europe
- HorseDialog Sponsors Current Eventing World Champion Ros Canter
- Survey Results Show Desire to Improve Awareness of Equine Herpes Virus (EHV)
- Zoetis Supports Veterinary Extramural Studies With Recognition Awards
- Zoetis receives European Commission Approval for Variation Group on Suvaxyn PRRS MLV Vaccine